Dr. Landgren on Using Daratumumab for Patients With Multiple Myeloma

C. Ola Landgren, MD, PhD
Published: Thursday, Mar 23, 2017



C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Daratumumab is a well-tolerated drug that Landgren says he prescribes to his patients often. One of the main issues with the agent, he adds, is that the first infusion can take a long time due to possible infusion-related adverse events, including shortness of breath, swelling in the mouth, itching, or a decrease in blood pressure.

However, Landgren says, as more practitioners and nurses get accustomed to administering the drug, it will be easier and quicker to start, slow down, and start again, Landgren explains. These reactions occur in approximately 30% to 50% of patients. Moreover, he adds, these reactions are not likely to occur in subsequent doses, citing clinical trial results and real-world settings.
 


C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Daratumumab is a well-tolerated drug that Landgren says he prescribes to his patients often. One of the main issues with the agent, he adds, is that the first infusion can take a long time due to possible infusion-related adverse events, including shortness of breath, swelling in the mouth, itching, or a decrease in blood pressure.

However, Landgren says, as more practitioners and nurses get accustomed to administering the drug, it will be easier and quicker to start, slow down, and start again, Landgren explains. These reactions occur in approximately 30% to 50% of patients. Moreover, he adds, these reactions are not likely to occur in subsequent doses, citing clinical trial results and real-world settings.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x